Deceptive Advertising! Claims Novo in GLP-1 Lawsuit Fallout
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Using multiple cards for rewards can significantly boost your benefits. Find out how to optimize your spending for maximum returns.
17,302 articlesTwo pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Looking for a few durable holdings to anchor a decades-long portfolio? Here are three monster stocks hold next—giants...
Alphabet reports results after the bell, but the line that matters most might be capex. This guide shows how data-cen...
FEG marks its five-year milestone by advancing SmartDeFi Launchpad, finalizing bonding curve testing, and expanding t...
As AI workloads surge, Celestica could play a pivotal role in data-center hardware. This guide breaks down the busine...
Bitcoin trades in a tight range after a sharp pullback, with big holders keeping their powder dry while retail buyers...
Can Lumen Technologies stock your journey toward wealth? This article breaks down the company’s shift toward AI infra...
New data shows Americans who reach 65 can expect nearly 20 more years of life. That longer horizon is forcing retiree...
News of potential price reductions for popular GLP-1 therapies sparked a slide in Novo Nordisk and Eli Lilly shares. ...
AI infrastructure has reshaped markets, but not every stock fits every investor. This guide explains what CoreWeave d...
Microsoft sits near a long-running price anchor as investors weigh AI incentives against macro risks. A decisive move...
Palo Alto Networks is trading lower as acquisition costs press on near-term guidance, even as AI security bets throug...